Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1338-1347

  Alghanem, Sarah ^a   Paterson, Iona ^b   Touw, Daan J ^c   Thomson, Alison H ^a,d  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c Apotheek Haagse Ziekenhuizen   (Netherlands)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

Between occasion variability; Lung infection; Model validation; Nephrotoxicity

Indexed keywords

CREATININE; GENTAMICIN; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYSTIC FIBROSIS; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; REFERENCE DATABASE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM;

BETWEEN-OCCASION VARIABILITY; LUNG INFECTION; MODEL VALIDATION; NEPHROTOXICITY;

ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BODY HEIGHT; BODY WEIGHT; CYSTIC FIBROSIS; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENTAMICINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; TOBRAMYCIN; YOUNG ADULT;

EID: 84884952131     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt035     Document Type: Article

References (51)

1. Cystic Fibrosis Trust UK. UK Cystic Fibrosis Registry Annual Data Report 2010. http://www.cftrust.org.uk/aboutcf/publications/cfregistryreports/ UK_CF_Registry_-_Annual_Data_Report_2010.pdf (1 February 2013, date last accessed).
2. The UK Cystic Fibrosis Trust AntibioticWorking Group. Antibiotic Treatment for Cystic Fibrosis. http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/ Antibiotic_treatment_for_Cystic_Fibrosis.pdf (1 February 2013, date last accessed).
3. Bertenshaw C, Watson A, Lewis S et al. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007; 62: 541-5.
4. Prestidge C, Chilvers MA, Davidson AGF et al. Renal function in pediatric cystic fibrosis patients in the first decade of life. Paediatr Nephrol 2011; 26: 605-12.
5. Smyth A, Tan KH-V, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-8.
6. Sweileh WM. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Fund Clin Pharmacol 2009; 23: 515-20.
7. Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011; 55: 2528-31.
8. Gá lvez R, Luengo C, Cornejo R et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011; 38: 146-51.
9. De Jager P, Van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-7.
10. Kelman A, Whiting B, Bryson S. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol 1982; 14: 247-56.
11. Campbell D, Thomson AH, Stack B. Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis. Ther Drug Monit 1999; 21: 281-8.
12. Proost JH, Meijer DKF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-63.
13. Beal S, Sheiner LB, Boeckman A et al. NONMEM User's Guides (1989- 2009). Ellicott City, MD: Icon Development Solutions, 2009.
14. Janmahasatian S, Duffull SB, Ash S et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
15. Mosteller R. Simplified calculation of body surface area. N Engl J Med 1987; 317: 1098.
16. WHO. BMI Classification. http://apps.who.int/bmi/index.jsp?intro Page=intro_3.html (1 February 2013, date last accessed).
17. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Duffull S, Kirkpatrick C, Begg E. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125-35.
19. Rosario MC, Thomson AH, Jodrell DI et al. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998; 46: 229-36.
20. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Meth Prog Bio 1999; 58: 51-64.
21. R Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
22. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58: 8-19.
23. Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
24. Bergstrand M, Hooker AC, Wallin JE et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-51.
25. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85-94.
26. Sheiner LB, Beal S. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
27. Hennig S, Standing JF, Staatz C et al. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clin Pharmacokinet 2013; in press.
28. Touw D, Knox A, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 2007; 6: 327-33.
29. Touw DJ, Vinks AATMM, Neef C. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Pharm World Sci 1996; 19: 142-51.
30. Aminimanizani A, Beringer PM, Kang J et al. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 2002; 50: 553-9.
31. Burkhardt O, Lehmann C, Madabushi R et al. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006; 58: 822-9.
32. Schentag JJ, Jusko WJ, Vance JW et al. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm 1977; 5: 559-77.
33. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977; 22: 364-70.
34. Beringer PM, Vinks AATMM, Jelliffe RW et al. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 2000; 44: 809-13.
35. Touw DJ, Vinks AATMM, Heijerman H et al. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1994; 16: 125-31.
36. Touw D, Vinks AATMM, Jacobs F et al. Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Ther Drug Monit 1996; 18: 562-9.
37. Hennig S, Norris R, Kirkpatrick CMJ. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis-a population pharmacokinetic study. Br J Clin Pharmacol 2008; 65: 502-10.
38. Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637-43.
39. Levy J, Smith A, Koup J et al. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984; 105: 117-24.
40. Kearns GL, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr 1982; 100: 312-8.
41. Soulsby N, Greville H, Coulthard K et al. What is the best method for measuring renal function in adults and children with cystic fibrosis? J Cyst Fibros 2010; 9: 124-9.
42. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Pediatric Child Health 2006; 42: 601-5.
43. Mann HJ, Canafax DM, Cipolle RJ et al. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985; 1: 238-43.
44. MacDonald NE, Anas NG, Peterson RG et al. Renal clearance of gentamicin in cystic fibrosis. J Pediatr 1983; 103: 985-90.
45. McKone EF, Goss CH, Aitken MLC. GFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130: 1441-7.
46. Kazazian HH. Population variation of common cystic fibrosis mutations. Hum Mutat 1994; 4: 167-77.
47. Gan K-H, Veeze HJ, Van Den Ouweland AMW et al. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995; 333: 95-9.
48. Kerem E, Corey M, Kerem B-S et al. The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (DF508). N Eng J Med 1990; 323: 1517-22.
49. Steinkamp G, Lütge M, Wurster U et al. Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. Eur J Pediatr 1986; 145: 526-31.
50. Smyth A, Lewis S, Bertenshaw C et al. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008; 63: 532-5.
51. Al-Aloul M, Miller H, Alapati S et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39: 15-20.